CervoMed Inc.

CRVO · Nasdaq · United States

Share price · CRVO

$1.45-1.16 (-44.44%) 3M

close as of 2026-11-18 · 24h delayed · vol 295K (0.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CRVO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026+29.2%

    Nothing announced by CRVO that day or the session before.

  2. 29 Oct 2026-20.8%
  3. 12 Oct 2026-22.0%
  4. 5 Oct 2026+9.6%

    Nothing announced by CRVO that day or the session before.

  5. 29 Sep 2026+7.9%
  6. 16 Jun 2026+82.3%
  7. 10 Jun 2026-22.1%
  8. 20 May 2026+12.1%

    Nothing announced by CRVO that day or the session before.

  9. 18 May 2026-11.6%
  10. 20 Feb 2026-11.5%

    Nothing announced by CRVO that day or the session before.

Share of unusual movement by asset

For each asset, the share of CRVO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
p38-alpha MAPKSmall molecule
Dementia with Lewy Bodies

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$3.7M$6.1M+ $14M short-term inv.$5.9M-$5.1M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$4.3M$22M+ $2.5M short-term inv.$6.6M-$6.9M operating cash flowreport ↗
2026-Q1$0$5.1M—+ $5.0M short-term inv.$8.0M-$8.0M operating cash flowreport ↗
2025-Q3$0.3M$6.0M—+ $18M short-term inv.$7.7M-$6.5M operating cash flowreport ↗
2025-Q2$1.8M$5.1M—+ $25M short-term inv.$6.3M-$6.5M operating cash flowreport ↗
2025-Q1$1.9M$4.8M$11M+ $25M short-term inv.$4.9M-$3.9M operating cash flowreport ↗
2024-Q3$1.9M$5.1M$7.7M+ $39M short-term inv.$4.8M-$4.8M operating cash flowreport ↗
2024-Q2$3.3M$3.8M$10M+ $35M short-term inv.$2.3M-$2.2M operating cash flowreport ↗
2024-Q1$2.4M$2.8M$6.4M$2.5M-$1.4M operating cash flowreport ↗
2023-Q3$1.5M$1.8M$10M—$2.7M operating cash flowreport ↗
2023-Q2$1.7M$0.1M$15M+ $0 short-term inv.$2.1M-$2.6M operating cash flowreport ↗
2023-Q1$1.4M$1.3M$15M+ $3.0M short-term inv.$4.1M-$5.0M operating cash flowreport ↗
2022-Q3$0$0.8M$4.8M+ $19M short-term inv.$2.8M-$2.8M operating cash flowreport ↗
2022-Q2—$2.1M$6.0M+ $23M short-term inv.$4.2M-$4.0M operating cash flowreport ↗
2022-Q1—$2.4M$9.9M+ $23M short-term inv.$4.5M-$4.7M operating cash flowreport ↗
2021-Q3—$2.1M$40M$12M-$3.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$4.0M$22M—+ $13M short-term inv.$6.7M-$23M operating cash flowreport ↗

CervoMed reported FY 2025 revenue of $4.01M, down 58.8% YoY, and R&D spend of $21.82M, up 16.1% YoY. Cash and equivalents were not disclosed. The company recorded a net loss of $26.97M and a quarterly net burn of $26.97M.

The filing centers on neflamapimod for dementia with Lewy bodies (DLB), non-fluent variant primary progressive aphasia (nfvPPA), recovery after stroke (RAS), and ALS. Management reported 16-week and 32-week extension results from the RewinD-LB trial and FDA alignment on key aspects of a planned Phase 3 DLB trial, which is expected to initiate in 2H26 subject to funding. For the Phase 2a trials initiated in 2025, enrollment completion is expected in 2Q26 for nfvPPA and mid-2026 for RAS, with initial nfvPPA biomarker data in mid-2026, topline RAS data in 2H26, initial nfvPPA clinical data in 2H26, topline nfvPPA data in 1H27, and first patient dosing in the EXPERTS-ALS trial expected at YE26.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$9.7M$19M$9.0M+ $30M short-term inv.$4.1M-$17M operating cash flowreport ↗
2023-FY$7.1M$8.4M$7.8M+ $0 short-term inv.$0.5M-$7.5M operating cash flowreport ↗
2022-FY$0$7.2M$10M+ $12M short-term inv.$3.9M-$15M operating cash flowreport ↗
2021-FY—$8.5M$37M+ $0 short-term inv.$6.0M-$15M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($3.2M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-18ALAM JOHN J · director, CEO & President, 10% ownerOpen-market purchase23,681$1.51$36KForm 4
2026-11-18ALAM JOHN J · director, CEO & President, 10% ownerOpen-market purchase76,319$1.53$117KForm 4
2026-10-22Winton Matthew · Chief Commercial and BusinessAward / grant (derivative)19,100——Form 4
2026-10-22De Rosch Mark · EVP, RA and GA and PgMAward / grant (derivative)19,100——Form 4
2026-10-22Blackburn Kelly · EVP, Clinical DevelopmentAward / grant (derivative)19,100——Form 4
2026-06-11BOGER JOSHUA S · director, 10% ownerOpen-market purchase955,414$3.14$3.0MForm 4
2026-06-11BOGER JOSHUA S · director, 10% ownerOpen-market purchase (derivative)955,414——Form 4
2026-06-11BOGER JOSHUA S · director, 10% ownerOpen-market purchase (derivative)955,414——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 36 reporting institutions held 1.8M shares ($7.0M, 11.7% of shares outstanding).

#InstitutionSharesValue
1MORGAN STANLEY739,892$2.9M
2VANGUARD CAPITAL MANAGEMENT LLC316,202$1.2M
3MILLENNIUM MANAGEMENT LLC208,908$823K
4GEODE CAPITAL MANAGEMENT, LLC74,371$293K
5RENAISSANCE TECHNOLOGIES LLC63,904$252K
6BlackRock, Inc.51,660$204K
7XTX Topco Ltd38,487$152K
8CITIZENS FINANCIAL GROUP INC/RI37,477$148K
9VANGUARD FIDUCIARY TRUST CO36,151$142K
10NORTHERN TRUST CORP30,044$118K
11Cetera Investment Advisers27,337$108K
12Savvy Advisors, Inc.25,922$102K
13STATE STREET CORP20,527$81K
14JANE STREET GROUP, LLC18,246$72K
15Russell Investments Group, Ltd.16,090$63K